TrialCancer science2015

A phase II study of bortezomib in patients with relapsed or refractory aggressive adult T-cell leukemia/lymphoma.

Kenji Ishitsuka et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.